Lonza to Expand Viral Therapy Business with Planned Construction of New Facility in Houston, TX
The state-of-the-art multi-purpose facility is expected to come on-line in the first half of 2017 and will include eight independent cGMP modular cleanrooms for 2,000 L-scale production in single-use bioreactors. Grade-B cleanrooms will also be constructed to continue the manufacture of EMA-regulated cell therapy products. The site master plan includes expanded process development and quality-control areas, shell space for future additional cleanrooms, and land for further potential expansions.
“The clinical landscape for targeted gene therapies continues to grow at a steady rate with new advancements in cancer immunotherapies and cardiovascular disease,” said Andreas Weiler, Ph.D, Head of Emerging Technologies for Lonza’s Pharma&Biotech segment. “This investment will allow Lonza to be well positioned to meet the demands of this growing market and to remain at the forefront of the viral gene therapy industry. Our viral team has more than 20 years of experience in viral vector gene therapy that, when combined with our newly constructed leading edge facility, will provide a key advantage to our customers and ultimately to their patients.
Most read news
Other news from the department manufacturing
These products might interest you
Biostat STR by Sartorius
Biostat STR Generation 3 Bioreactors
Engineered for Ultimate Upstream Performance
Ambr® 250 Modular by Sartorius
Mini bioreactors for cell and gene therapies with high scalability
Maximise your process development with reliable single-use vessels
Ambr® 250 HT Consumables by Sartorius
Efficient bioprocesses with single-use bioreactors
Minimise cleaning effort and maximise flexibility for cell and microbial cultures
Flexcell Systems by Dunn
Flexcell Cell Stretching Bioreactors for Life Science Research
Used in over 1300 laboratories worldwide, and cited in over 4000 research publications
Brooks Instrument SLA Biotech-Serie by Brooks Instrument
Control bioprocesses efficiently and precisely with flow controllers for biotechnology applications
The SLA Biotech series has been developed specifically for the requirements in bioprocesses
SLAMf Biotech-Serie Massendurchflussregler by Brooks Instrument
SLAMf Mass Flow Controllers Designed Specifically for Biotech (IP66 / NEMA 4X)
Special equipment for biotech process plants, suitable for splash water and high-pressure cleaning
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.